89 related articles for article (PubMed ID: 21223717)
1. [Study on PI3K inhibitor LY294002 for chemotherapeutic sensitization in diffuse large B cell lymphoma cell lines].
Zhang TC; Chu HJ; Zhao JQ; Zhou XY; Shi DR
Zhonghua Xue Ye Xue Za Zhi; 2010 Oct; 31(10):671-4. PubMed ID: 21223717
[TBL] [Abstract][Full Text] [Related]
2. [Effects of AKT protein kinase activation on biologic behavior of diffuse large B cell lymphoma cells].
Zhang TC; Zhou XY; Yu BH; Zhang TM; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2007 May; 36(5):318-23. PubMed ID: 17706139
[TBL] [Abstract][Full Text] [Related]
3. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
4. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival.
Uddin S; Hussain AR; Siraj AK; Manogaran PS; Al-Jomah NA; Moorji A; Atizado V; Al-Dayel F; Belgaumi A; El-Solh H; Ezzat A; Bavi P; Al-Kuraya KS
Blood; 2006 Dec; 108(13):4178-86. PubMed ID: 16946303
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.
Lv X; Feng L; Ge X; Lu K; Wang X
J Exp Clin Cancer Res; 2016 Jul; 35(1):106. PubMed ID: 27364124
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Yuan T; Zhang F; Zhou X; Li Y; Zhang Y; Xu Y; Wang X
Oncol Lett; 2019 Apr; 17(4):3719-3726. PubMed ID: 30881494
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
9. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
10. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G
Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007
[TBL] [Abstract][Full Text] [Related]
11. Mutations of the PIK3CA gene in diffuse large B cell lymphoma.
Baohua Y; Xiaoyan Z; Tiecheng Z; Tao Q; Daren S
Diagn Mol Pathol; 2008 Sep; 17(3):159-65. PubMed ID: 18382359
[TBL] [Abstract][Full Text] [Related]
12. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
13. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis.
Suzuki E; Umezawa K; Bonavida B
Oncogene; 2007 Sep; 26(42):6184-93. PubMed ID: 17420722
[TBL] [Abstract][Full Text] [Related]
14. Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.
Uddin S; Bu R; Ahmed M; Hussain AR; Ajarim D; Al-Dayel F; Bavi P; Al-kuraya KS
Leuk Lymphoma; 2010 Jul; 51(7):1305-14. PubMed ID: 20443680
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
Urol Int; 2011; 87(1):105-13. PubMed ID: 21597260
[TBL] [Abstract][Full Text] [Related]
16. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
McDonald GT; Sullivan R; Paré GC; Graham CH
Exp Cell Res; 2010 Nov; 316(19):3197-206. PubMed ID: 20736003
[TBL] [Abstract][Full Text] [Related]
18. Arsenic disulfide induces apoptosis of human diffuse large B cell lymphoma cells involving Bax cleavage.
Wang L; Liu X; Li X; Lv X; Lu K; Chen N; Li P; Wang X
Oncol Rep; 2013 Nov; 30(5):2427-34. PubMed ID: 24026139
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
Urol Int; 2011; 86(3):346-54. PubMed ID: 21273759
[TBL] [Abstract][Full Text] [Related]
20. [Effect and mechanism of LY294002 on growth of fibrosarcoma cell line HT1080].
Zhou H; Huang XY; Yang T; Wang T; Xu D; Wen FQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jan; 41(1):20-3. PubMed ID: 20369463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]